Skip to main content

Prelude Therapeutics Inc

PRLD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001678660

No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding Prelude Therapeutics Inc changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of PRLD: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders6055−5
Shares31.2M31.5M+309.0K (+1.0%)
Value$188.3M$179.6M−$8.69M (−4.6%)

New holders (8)

Institutions that held Prelude Therapeutics Inc at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to PRLD in Q1 2023
InstitutionSharesValue% of portfolio
Boxer Capital, LLC699,047$3.98M0.20%
Jacobs Levy Equity Management, Inc84,667$482.6K0.00%
HRT Financial LP22,175$126.0K0.00%
Virtu Financial LLC11,201$64.0K0.01%
Two Sigma Securities, LLC10,922$62.3K0.01%
Cubist Systematic Strategies, LLC8,778$50.0K0.00%
Point72 Middle East FZE1,680$9.58K0.00%
Point72 Asset Management, L.P.1,222$6.96K0.00%

Sold out (13)

Institutions that held Prelude Therapeutics Inc at the end of Q4 2022 and filed for Q1 2023 without it.